What You Should Know:
- C2i Genomics, a cancer intelligence company, today announced a collaboration with Riken Genesis Co., Ltd. (RG), a company specializing in providing the service of personalized medicine based on contract analysis of next-generation sequencing and exomes. The two companies have entered a collaboration agreement to bring MRD cancer monitoring to Japan for pharmaceutical and clinical research.
- Under this agreement, RG will work with C2i Genomics to commercialize
Read More
genomics
What Impact Could AI Have On Genetic Testing?
The sequencing and analysis of human DNA have advanced significantly since the initial draft of a human genome that was published as part of the Human Genome Project. With DNA sequencing becoming increasingly cost-effective, the market for genetic testing is growing at an accelerating rate – the market for Next Generation Sequencing (NGS) services has an estimated annual growth of 18.3% from 2022 to 2030. AI presents a range of possibilities for this rapidly growing field, and in this article,
Read More
Tempus Forms Multi-omics Collaboration With Actuate Therapeutics
What You Should Know:
- Tempus, the $10B artificial intelligence and precision medicine company, announced their first multi-omics collaboration with Actuate Therapeutics, in which datasets of different omic groups – genomics, transcriptomics, epigenomics, and others are combined during analysis to improve research and enable new discoveries, including ones that would have been missed with a single method alone.
- This multi-omics approach is being used by Actuate Therapeutics in support
Read More
From Telemedicine to Complete Virtual Care and Beyond
Telemedicine has helped improve the quality of life of patients in every corner of the world and has been successfully utilized to provide convenient care to people with limited or no access to health services. Today, worldwide digital interconnectivity is growing, enabling telehealth to advance health equity, bring access to care for underserved regions and meet the urgent, primary and behavioral healthcare needs of an exploding global population.
It has been a remarkable journey for the
Read More
Startup Velsera Launches to Advance Precision Health Through Data-Driven Solutions
What You Should Know:
- New company Velsera was announced at the J.P. Morgan Healthcare Conference supported by thematic-focused impact fund Summa Equity (“Summa”).
- Velsera sets out to amplify the impact of clinicians, researchers and scientists for the benefit of patients around the world. Velsera creates a software platform out of science, technology, and informatics, making data actionable, accelerating the pace and potential of multi-omics.
- Velsera, headquartered in
Read More
Liver Cancer Awareness – Here’s What You Need to Know in 2023
By the end of 2022, nearly 42,00 new cases of primary liver cancer will be diagnosed in the United States. In fact, liver cancer incidence rates have more than tripled since 1980, marking an increased need for better detection and diagnosis.
We might not talk about liver cancer as much as we do breast or lung cancer, but it’s a real threat to millions of Americans – and we need to continue spreading awareness.
Early detection is especially critical in treating liver cancer.
Read More
C2i Genomics & AstraZeneca Partner to Advance Cancer Therapy
What You Should Know:
- C2i Genomics, a cancer intelligence company, today announced a strategic collaboration with AstraZeneca, a global life sciences and pharmaceutical leader.
- The two companies have collaborated to evaluate the potential of whole-genome minimal residual disease (MRD) testing across solid cancers.
- Expanding on a completion of AstraZeneca’s accelerator BeyondBio SCALE program for start-ups and successful technology validation, C2i Genomics and AstraZeneca
Read More
WellSpan Health & Helix to Create Population Genomics Program
What You Should Know:
- WellSpan Health and Helix, the nation’s leading population genomics and viral surveillance company, announced today a partnership to create a comprehensive population genomics program designed to improve patient healthcare outcomes by integrating genetic insights into clinical care and research.
- Patients who are interested can have a DNA sample collected to generate genomic data. Once obtained, with their consent, the results from their sample will be integrated
Read More
JPMorgan Establishes Life Sciences Private Equity Division
What You Should Know:
- J.P. Morgan Asset Management announced the establishment of a new life sciences private equity team, Life Sciences Private Capital.
- The new team will focus on investing in both early and growth-stage healthcare companies across multiple strategies aligned to specific market opportunities, with a focus on novel therapeutics and technologies in several target areas including Genetic Medicine, Oncology, Neurodegenerative Disease, Rare Diseases, Autoimmunity,
Read More
Mount Sinai Develops Employee Health Contact Tracing Database to Mitigate COVID-19 Spread
What You Should Know:
- Mount Sinai researchers have developed an Employee Health COVID-19 REDCap Registry to address the need for contact tracing and agile exposure investigations to mitigate the spread of COVID-19 among hospital staff.
- Employee Health COVID-19 REDCap Registry is a cloud-based digital framework using the Research Electronic Data Capture web application—to track and reduce the spread of the virus across the Mount Sinai Health System including 8 hospitals and more than
Read More
